ALA
ABBV icon

Atlas Legacy Advisors’s AbbVie ABBV Stock Holding History

Atlas Legacy Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$623K Buy
2,607
+917
+54% +$197K 0.09% 126
2026
Q1 		$367K Sell
1,690
-749
-31% -$166K 0.07% 150
2025
Q4 		$545K Buy
2,439
+83
+4% +$18.9K 0.1% 132
2025
Q3 		$546K Buy
2,356
+1,074
+84% +$219K 0.11% 123
2025
Q2 		$238K Buy
1,282
+229
+22% +$42.6K 0.05% 164
2025
Q1 		$221K Sell
1,053
-560
-35% -$109K 0.06% 161
2024
Q4 		$287K Buy
+1,613
New +$297K 0.07% 145

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Atlas Legacy Advisors's ABBV Position: Q2 2026 in Review

Atlas Legacy Advisors increased its AbbVie (ABBV) stake by 54% in Q2 2026, buying an estimated $197K and bringing the position to 2,607 shares worth $623K. The position accounts for 0.09% of the portfolio, ranked #126.

Atlas Legacy Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Atlas Legacy Advisors held 2,607 shares of AbbVie worth $623K as of Q2 2026.
  • Atlas Legacy Advisors bought 917 AbbVie shares in Q2 2026, an estimated $197K.
  • AbbVie made up 0.09% of Atlas Legacy Advisors's portfolio in Q2 2026, its #126 holding.
  • Atlas Legacy Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Atlas Legacy Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.